Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Annelie A H MustersF L van LookerenL F van der GangM A Middelkamp-HupAngela Leigh-Ann L BosmaN T JessurunH LapeereA L NguyenW OuwerkerkS de SchepperL A A GerbensP I SpulsPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Real-world reported AEs captured in AD patient registries can add information on the estimated incidence of AEs and benefit clinical decision aids. Future studies using data derived from the TREAT NL registry combined with data from other registries within the TREAT Registry Taskforce will provide more information on (rare) AEs associated with immunomodulating therapy in AD patients.
Keyphrases
- atopic dermatitis
- end stage renal disease
- electronic health record
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- health information
- risk factors
- prognostic factors
- case report
- healthcare
- decision making
- patient reported outcomes
- cell therapy
- social media
- patient reported
- smoking cessation